| 摘要 |
(A) New antiviral and antitumour compsns. contain (1) an active substance with antiviral and antitumour activity and (2) an adjuvant cpd. which contains in its molecule at least one lipophilic- and at least one hydrophilic-gp. (B) New pharmaceutical prepns. intended to administration before, simultaneously with or after pharmaceutical prepns. with antiviral and antitumour activity, which increase the activity of the antiviral/antitumour prepns. contain as the synergistically acting active substance at least one cpd. contg. in its molecule at least one lipophilic- and at least one hydrophilic-gp. Pref. antitumour/antiviral active substances xanthate derivs. of formula (I) (R1 is norbornyl, tricyclodecyl, benzyl, 3-20C (cyclo)alkyl, furyl, pyridyl, quinuclidinyl, 3-20C alkyl substd. by at least one OH or 1-4C alkoxy or halogenation, or 3-20C cycloalkyl substd. by at least one OH, 1-4C alkoxy or 1-4C alkyl or halogen atom; R2 is one equiv. of a mono- or polyvalent metal ion, 2,3-dihydroxypropyl, omega-hydroxy-(1-4C alkoxy)-methyl, or 1-6C alkyl opt. substd. by at least one OH, 1-4C alkoxy, amino, di(1-4C alkyl)amino or tri-(1-4C alkyl)amino or halogen atom). The adjuvant cpd. (component 2) pref. carries a 6-18C aliphatic gp. as the lipophilic gp. and 1-2 carboxy, sulphate, sulphonate or phospate gps. as hydrophilic gps. and may be in the form of a pharmaceutically acceptable salt. -
|
